| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 1370512 | Bioorganic & Medicinal Chemistry Letters | 2015 | 4 Pages |
Abstract
We tested cytotoxicity of aminoferrocene-based prodrugs towards human androgen-responsive and unresponsive prostate cancer cell lines LNCaP and DU-145 correspondingly. Two prodrugs were selected, which are both activated at elevated concentrations of ROS with generation of quinone methide (antioxidant system inhibitor) and iron-containing compounds (N-benzylaminoferrocene (prodrug 1) and Fe salts (2)). We observed that only prodrug 1 is active against the selected prostate cancer cells (IC50 = 11–27 μM) and its activity correlates with the high cell-membrane permeability and increased production of intracellular ROS.
Graphical abstractFigure optionsDownload full-size imageDownload as PowerPoint slide
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Margot Schikora, Alexander Reznikov, Liudmila Chaykovskaya, Olga Sachinska, Lubov Polyakova, Andriy Mokhir,